Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s advanced de novo antibody design models. AMD will also make a $20M investment in Absci, structured as a private investment in public equity, PIPE, underscoring the growing demand for innovative AI applications in drug discovery.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Absci price target lowered to $5 from $6 at KeyBanc
- Absci, Invetx partner to bring AI drug creation platform to animal health
- Absci highlights progress, updates across proprietary pipeline
- Cathie Wood’s ARK Investment bought 202.6K shares of Absci today
- Cathie Wood’s ARK Investment bought 137.9K shares of Absci today
Questions or Comments about the article? Write to editor@tipranks.com